Sabby Management’s ProQR Therapeutics PRQR Stock Holding History

Sabby Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-172,160	Closed	-$529K	–	171
2018 Q1	$529K	Sell	172,160 -175,085	-50%	-$563K	0.06%	94
2017 Q4	$1.12M	Buy	+347,245	New	+$1.25M	0.1%	69
2017 Q1	–	Sell	-40,000	Closed	-$196K	–	298
2016 Q4	$196K	Sell	40,000 -18,910	-32%	-$97.4K	0.01%	240
2016 Q3	$393K	Sell	58,910 -51,090	-46%	-$281K	0.01%	239
2016 Q2	$532K	Sell	110,000 -39,934	-27%	-$205K	0.03%	209
2016 Q1	$732K	Buy	149,934 +110,063	+276%	+$560K	0.04%	184
2015 Q4	$346K	Buy	39,871 +17,921	+82%	+$206K	0.02%	262
2015 Q3	$320K	Sell	21,950 -61,050	-74%	-$1.02M	0.01%	321
2015 Q2	$1.38M	Sell	83,000 -41,380	-33%	-$780K	0.05%	201
2015 Q1	$2.72M	Sell	124,380 -128,703	-51%	-$2.66M	0.11%	120
2014 Q4	$5.48K	Sell	253,083 -128,166	-34%	-$1.95M	0.17%	66
2014 Q3	$6.55K	Buy	+381,249	New	+$6.11M	0.25%	52

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Sabby Management's PRQR Position: Q2 2018 in Review

Sabby Management sold out of ProQR Therapeutics (PRQR) in Q2 2018, closing a stake of 172,160 shares — an estimated $529K sold.

Sabby Management first reported a position in PRQR in Q3 2014 and held it in 12 quarters. The position peaked at $2.72M in Q1 2015. 25 funds tracked by Wall St. Rank hold PRQR as of Q2 2018.

Sabby Management reported no remaining ProQR Therapeutics position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 172,160 ProQR Therapeutics shares in Q2 2018, an estimated $529K.
Sabby Management first reported a position in ProQR Therapeutics in Q3 2014 and held it in 12 quarters.
Sabby Management's ProQR Therapeutics position peaked at $2.72M in Q1 2015.
25 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.